Aptose Biosciences (TSX:APS) Tax Provision : C$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Aptose Biosciences Tax Provision?

Aptose Biosciences's tax provision for the three months ended in Dec. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Aptose Biosciences Tax Provision Historical Data

The historical data trend for Aptose Biosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Tax Provision Chart

Aptose Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

Aptose Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Aptose Biosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Aptose Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (TSX:APS) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

APTOF:USA 0UI8:UK LTI0:Germany

Address

66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6

Website

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Executives

Bernd Robert Seizinger	Director
William Glenn Rice	Director, Senior Officer
Erich Platzer	Director
Rafael Bejar	Senior Officer
Warren Whitehead	Director
Gregory Kwok Lee Chow	Senior Officer
Jotin Marango	Senior Officer

Aptose Biosciences Headlines

No Headlines